Yes, Remicade is a biologic drug. It is one of the most well-known biologics on the market, FDA-approved to treat several autoimmune and inflammatory conditions. Its active ingredient, infliximab, is a large, complex protein made from living cells, which is the defining feature that separates biologics from conventional medications.
What Makes Remicade a Biologic
The key distinction between biologics and traditional drugs comes down to how they’re made. Traditional medications are small molecules created through chemical synthesis in a lab. Biologics are large, complex proteins extracted from or produced by living organisms. Remicade is manufactured using mouse myeloma cells that have been engineered to produce the infliximab protein. These cells are essentially living factories, secreting the antibody that becomes the final drug product.
This matters because the resulting molecule is far larger and more structurally complex than a typical pill you’d pick up at a pharmacy. That complexity is also why Remicade can’t be taken orally. It would be broken down in your digestive system before it could work. Instead, it’s given as an intravenous infusion, delivered directly into the bloodstream at a clinic or infusion center.
How Remicade Works in the Body
Remicade belongs to a specific class of biologics called TNF-alpha inhibitors. TNF-alpha is a protein your immune system produces to trigger inflammation. In autoimmune diseases, the body overproduces TNF-alpha, causing chronic inflammation that damages healthy tissue in the joints, gut, skin, or spine.
Remicade works by binding directly to TNF-alpha molecules and neutralizing them before they can fuel that inflammatory cycle. Each Remicade molecule can latch onto two TNF-alpha molecules at once, and up to three Remicade molecules can bind a single cluster of TNF-alpha. This creates large protein complexes that effectively sweep up excess TNF-alpha from the bloodstream and inflamed tissues. The result, for many patients, is a significant reduction in pain, swelling, and tissue damage.
Conditions Remicade Treats
Remicade is approved for a broader range of conditions than many people realize. The full list of FDA-approved uses includes:
- Crohn’s disease (adults and children 6 and older)
- Ulcerative colitis (adults and children 6 and older)
- Rheumatoid arthritis
- Ankylosing spondylitis (inflammatory arthritis of the spine)
- Psoriatic arthritis
- Plaque psoriasis
The common thread across all of these is an overactive immune response driven by TNF-alpha. While each condition affects a different part of the body, the underlying inflammatory mechanism is similar enough that the same biologic can address it.
What the Infusion Schedule Looks Like
Because Remicade is a biologic given intravenously, the treatment schedule is quite different from taking a daily pill. For most conditions, you receive three initial “loading” infusions at weeks 0, 2, and 6. After that, maintenance infusions typically happen every 6 to 8 weeks, depending on the condition being treated. Ankylosing spondylitis, for example, uses a 6-week cycle, while Crohn’s disease and ulcerative colitis follow an 8-week schedule.
The dose is weight-based. Most conditions call for 5 mg per kilogram of body weight per infusion, though rheumatoid arthritis uses a lower dose of 3 mg/kg. Each infusion session itself typically takes about two hours, plus additional monitoring time afterward.
Risks That Come With Suppressing Immunity
Because Remicade works by dialing down part of your immune system, it carries risks that are common across TNF-alpha inhibitors. The most significant concern is a higher susceptibility to infections, including serious ones like tuberculosis. Before starting treatment, you’ll typically be screened for latent tuberculosis and other infections. Patients on Remicade also face a slightly elevated risk of certain cancers, particularly lymphoma. These risks are outlined in the drug’s most prominent safety warnings.
Infusion reactions are another possibility. Some people experience fever, chills, chest tightness, or changes in blood pressure during or shortly after an infusion. These reactions can range from mild to serious, and infusion centers monitor you closely for this reason. Over time, some patients develop antibodies against infliximab itself, which can reduce the drug’s effectiveness or increase the likelihood of reactions. This is one reason Remicade is often prescribed alongside another immune-suppressing medication, to help prevent that antibody formation.
Remicade Biosimilars
Because Remicade is a biologic, it can’t have a true “generic” the way a traditional drug can. The manufacturing process using living cells is too complex to replicate exactly. Instead, companies develop what are called biosimilars: drugs that are highly similar to the original biologic and produce no meaningful clinical differences. The FDA has approved several infliximab biosimilars, including Inflectra, Renflexis, and Avsola, all of which are currently available in the United States. A fourth, Ixifi, has FDA approval but has not yet launched.
Biosimilars tend to cost less than the original brand-name biologic, and your insurance plan or doctor may recommend switching to one. The transition is generally considered safe, since biosimilars must meet rigorous standards demonstrating they work the same way as the reference drug.